ACCELERATE2030
Global Finalist Profile“Landcent is a global health innovation company on a mission to accelerate the fight against infectious disease of poverty by developing and delivering affordable, sustainable solutions that are safe to use at scale.”
Landcent
China
The Problem
After decades of progress, malaria is on the rise again. Today, it kills 1200 people a day, with close to 70% being children below 5. This amounts to a child dying every 2 minutes, from this entirely preventable disease.
Unfortunately, 93% of the cases of malaria happen in sub-Saharan Africa, which includes some of the poorest countries in the world. Resources are scarce, global funding has been proven woefully inadequate and any increased availability remains uncertain. In the last few years, the problem has been compounded by growing insecticide resistance observed in many countries.
Apart from lives lost, malaria has a direct correlation to financial health: Malaria endemic countries have per capita income levels that are 70% lower than those of non-endemic countries.
The Solution
Landcent has a unique two-track approach to tackling malaria. Track 1 is to leapfrog current, proven technologies and design next-generation versions that will disrupt the sector. Landcent has developed an Indoor Residual Spray (IRS) with twice the residual effect of any IRS in the market and a Long-Lasting Insecticidal Net (LLIN), which incorporates two insecticides reducing the ability for mosquitoes to build resistance.
Track 2 develops safe and sustainable active ingredients (a.i.). We have screened a total of 57,407 natural compounds in phase I and 14 promising candidates are being evaluated for the next stage of product development.
Media Inquiries
Investors and Partners
ACCELERATE2030
Global Finalist Profile
“Landcent is a global health innovation company on a mission to accelerate the fight against infectious disease of poverty by developing and delivering affordable, sustainable solutions that are safe to use at scale.”
Landcent
China
JAVIER SOTO
The Problem
After decades of progress, malaria is on the rise again. Today, it kills 1200 people a day, with close to 70% being children below 5. This amounts to a child dying every 2 minutes, from this entirely preventable disease.
Unfortunately, 93% of the cases of malaria happen in sub-Saharan Africa, which includes some of the poorest countries in the world. Resources are scarce, global funding has been proven woefully inadequate and any increased availability remains uncertain. In the last few years, the problem has been compounded by growing insecticide resistance observed in many countries.
Apart from lives lost, malaria has a direct correlation to financial health: Malaria endemic countries have per capita income levels that are 70% lower than those of non-endemic countries.
The Solution
Landcent has a unique two-track approach to tackling malaria. Track 1 is to leapfrog current, proven technologies and design next-generation versions that will disrupt the sector. Landcent has developed an Indoor Residual Spray (IRS) with twice the residual effect of any IRS in the market and a Long-Lasting Insecticidal Net (LLIN), which incorporates two insecticides reducing the ability for mosquitoes to build resistance.
Track 2 develops safe and sustainable active ingredients (a.i.). We have screened a total of 57,407 natural compounds in phase I and 14 promising candidates are being evaluated for the next stage of product development.